These two authors contributed equally to this work.
Cancer Cell Biology
The tetraspanin CD9 inhibits the proliferation and tumorigenicity of human colon carcinoma cells
Article first published online: 20 JUN 2007
DOI: 10.1002/ijc.22902
Copyright © 2007 Wiley-Liss, Inc.
Additional Information
How to Cite
Ovalle, S., Gutiérrez-López, M. D., Olmo, N., Turnay, J., Lizarbe, M. A., Majano, P., Molina-Jiménez, F., López-Cabrera, M., Yáñez-Mó, M., Sánchez-Madrid, F. and Cabañas, C. (2007), The tetraspanin CD9 inhibits the proliferation and tumorigenicity of human colon carcinoma cells. Int. J. Cancer, 121: 2140–2152. doi: 10.1002/ijc.22902
Publication History
- Issue published online: 25 SEP 2007
- Article first published online: 20 JUN 2007
- Manuscript Accepted: 9 MAY 2007
- Manuscript Received: 22 SEP 2006
Funded by
- Fundación de Investigación Médica Mutua Madrileña
- Dirección General de Investigación, Ministerio de Educación y Ciencia. Grant Numbers: SAF2004-01715, BFU2005-02671
- Consejo Superior de Investigaciones Científicas (CSIC)
- Abstract
- Article
- References
- Cited By
Keywords:
- CD9;
- TNF-α;
- proliferation;
- tumorigenicity;
- tetraspanin
Abstract
The implication of the tetraspanin CD9 in cancer has received much recent attention and an inverse correlation between CD9 expression and the metastatic potential and cancer survival rate has been established for different tumor types. In contrast to the well-established role of CD9 in metastasis, very little is known about the involvement of this tetraspanin in the process of development of primary tumors. In the present study, we present evidence on the implication of CD9 in colon carcinoma tumorigenesis. We report here that ectopic expression of CD9 in colon carcinoma cells results in enhanced integrin-dependent adhesion and inhibition of cell growth. Consistently with these effects, treatment of these cells with anti-CD9-specific antibodies resulted in (i) increased β1 integrin-mediated cell adhesion through a mechanism involving clustering of integrin molecules rather than altered affinity; (ii) induction of morphological changes characterized by the acquisition of an elongated cell phenotype; (iii) inhibition of cell proliferation with no significant effect on cell survival; (iv) increased expression of membrane TNF-α, and finally (v) inhibition of the in vivo tumorigenic capacity in nude mice. In addition, through the use of selective blockers of TNF-α, we have demonstrated that this cytokine partly mediates the antiproliferative effects of CD9. These results clearly establish for the first time a role for CD9 in the tumorigenic process. © 2007 Wiley-Liss, Inc.

1097-0215/asset/olbannerleft.jpg?v=1&s=45719cd7de57873027993264fcc568b335a8cd56)
1097-0215/asset/olbannerright.jpg?v=1&s=5e0fba63c1309b3036eb9215a0e1e83dd02efd19)
